Investor Presentaiton
APPENDIX
שיי
UPMC: unique partnership & research opportunity
Our Chapter 20 Clinical Registrant license, awarded in partnership with University of Pittsburgh Medical Center ("UPMC"), provides an
opportunity for Parallel to (i) study the beneficial effects of cannabis and (ii) operate facilities in Pennsylvania
PARTNER OVERVIEW
UPMC is a $21 billion integrated global health enterprise that has
89K+ employees, 40 hospitals, 700+ clinical locations, and a
3.7M+ member health insurance division
UPMC is a leading American health care provider - ranked in U.S.
News and World Report "Honor Roll" of the approximately 15 to
20 best hospitals in America - for 15+ years
UPMC is one of only eight academic institutions in Pennsylvania
that has been selected to receive the Chapter 20 research license
in conjunction with the state's medical cannabis program
University of
Pittsburgh
UPMC
LIFE CHANGING MEDICINE
CLINICAL REGISTRANT LICENSE OVERVIEW¹
Through our partnership with UPMC, we are one of only 8
companies in Pennsylvania operating under the Chapter 20
Clinical Registrant licensure program, which includes:
A cultivation and processing license (1 of up to 25)
A retail license for up to six retail stores (103 exist today,
non-Clinical Registrant license-holders can only operate
three)
A clinical research license to conduct studies and human
trials utilizing cannabinoids to treat acute medical
conditions
Parallel is participating in research studies, one of which
will initially focus on Sickle Cell Disease ("SCD")
SCD afflicts 100,000+ people annually and
disproportionally affects the African-American
community and is typically treated with opiates
Lifetime treatment cost can often exceed $1M,
providing an opportunity for significant cost savings
with cannabis
10 year partnership allows Parallel to conduct future research
initiatives with proprietary products and formulations
1. See "Forward-Looking Statements" disclaimer on pages 3-4 and financial assumptions on pages 57-58.
53View entire presentation